Dr. Steve N. Slilaty, CEO of Sunshine Biopharma stated:

These data indicate that Adva-27a will likely not be toxic or damaging to healthy tissue, a key component for our planned clinical trials, as toxicity is what stops most drugs in early development. This further confirms that Adva-27a will have great utility for cancer therapy in humans, particularly in view of the fact that twenty-four micromolar is over three times the actual concentration estimated to ultimately be used in patient therapy.

Click here to view the full press release.